Table 1 Demographics and baseline characteristics of patients (N = 46)

Demographics

 Male, n (%)

19 (41)

 Age, years (mean ± SD)

73 ± 12

 BMI, Kg.m^− 2 (mean ± SD)

27 ± 5

 Previous stroke/TIA, n (%)

6 (13)

 Hypertension, n (%)

28 (61)

 Diabetes Mellitus, n (%)

14 (30)

 Dyslipidemia, n (%)

27 (59)

 Tobacco, n (%)

4 (9)

 Previous MI, n (%)

2 (4)

 Atrial Fibrillation, n (%)

20 (43)

Chronic Medication, n (%)

 Antiplatelet

18 (39)

 Statin

17 (37)

 Beta-Blocker

10 (22)

 ACEI/ARB

15 (33)

 CCB

9 (20)

Stroke characteristics

 Etiology (TOAST), n (%)

  Large Vessel

6 (13)

  Cardioembolic

18 (39)

  Small vessel

2 (4)

  Other

1 (2)

  Undetermined

12 (26)

 Occlusion of affected MCA

16 (35)

 Baseline NIHSS score [median(IQR)]

14 (9–22)

Neuroimaging [median(IQR)]

 Infarct Volume, mL

19 (2–139)

 Leucoencephalopathy grade (VanSwieten scale [33])

2 (1–3)

Laboratorial (mean ± SD)

 Total cholesterol, mg/dL

174 ± 72

 LDL cholesterol, mg/dL

105 ± 42

 HDL cholesterol, mg/dL

46 ± 11

 Triglycerides, mg/dL

111 ± 68

 Glucose, mg/dL

140 ± 81

 HbA1C, %

6.4 ± 1.4

 Creatinine, mg/dL

1.0 ± 1.0

Renal Function

 eGFR, ml/min/1.73 m²

80 ± 39

  CDK–EPI Stage 0–1, n (%)

10 (22)

  CDK–EPI Stage 2, n (%)

23 (50)

  CDK–EPI Stage 3, n (%)

13 (28)

  CDK–EPI Stage 4, n (%)

1 (2)

  CDK–EPI Stage 5, n (%)

1 (2)